Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat

Elizabeth A. Muellenbach, Cody J. Diehl, Mary K. Teachey, Katherine A. Lindborg, Tara L. Archuleta, Nicholas B. Harrell, Gaby Andersen, Veronika Somoza, Oliver Hasselwander, Markus Matuschek, Erik J Henriksen

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Oxidative stress and protein glycation can contribute to the development of insulin resistance and complications associated with type 2 diabetes mellitus. The antioxidant α-lipoic acid (ALA) reduces oxidative stress and the formation of advanced glycation end products (AGEs) and improves insulin sensitivity in skeletal muscle and liver. The AGE inhibitor pyridoxamine (PM) prevents irreversible protein glycation, thereby reducing various diabetic complications. The potential interactive effects of ALA and PM in the treatment of whole-body and skeletal muscle insulin resistance have not been investigated. Therefore, this study was designed to determine the effects of combined ALA and PM treatments on reducing muscle oxidative stress and ameliorating insulin resistance in prediabetic obese Zucker rats. Obese Zucker rats were assigned to either a control group or to a treatment group receiving daily injections of the R-(+)-enantiomer of ALA (R-ALA, 92 mg/kg) or PM (60 mg/kg), individually or in combination, for 6 weeks. The individual and combined treatments with R-ALA and PM were effective in significantly (P < .05) reducing plantaris muscle protein carbonyls (33%-40%) and urine-conjugated dienes (22%-38%), markers of oxidative stress. The R-ALA and PM in combination resulted in the largest reductions of fasting plasma glucose (23%), insulin (16%), and free fatty acids (24%) and of muscle triglycerides (45%) compared with alterations elicited by individual treatment with R-ALA or PM. Moreover, the combination of R-ALA and PM elicited the greatest enhancement of whole-body insulin sensitivity both in the fasted state and during an oral glucose tolerance test. Finally, combined R-ALA/PM treatments maintained the 44% enhancement of in vitro insulin-mediated glucose transport activity in soleus muscle of obese Zucker rats treated with R-ALA alone. Collectively, these results document a beneficial interaction of the antioxidant R-ALA and the AGE inhibitor PM in the treatment of whole-body and skeletal muscle insulin resistance in obese Zucker rats.

Original languageEnglish (US)
Pages (from-to)1465-1472
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume57
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Pyridoxamine
Zucker Rats
Thioctic Acid
Advanced Glycosylation End Products
Insulin Resistance
Antioxidants
Skeletal Muscle
Oxidative Stress
Therapeutics
Insulin
Glucose
Muscles
Muscle Proteins
Diabetes Complications
Glucose Tolerance Test
Heat-Shock Proteins
Nonesterified Fatty Acids

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat. / Muellenbach, Elizabeth A.; Diehl, Cody J.; Teachey, Mary K.; Lindborg, Katherine A.; Archuleta, Tara L.; Harrell, Nicholas B.; Andersen, Gaby; Somoza, Veronika; Hasselwander, Oliver; Matuschek, Markus; Henriksen, Erik J.

In: Metabolism: Clinical and Experimental, Vol. 57, No. 10, 10.2008, p. 1465-1472.

Research output: Contribution to journalArticle

Muellenbach, EA, Diehl, CJ, Teachey, MK, Lindborg, KA, Archuleta, TL, Harrell, NB, Andersen, G, Somoza, V, Hasselwander, O, Matuschek, M & Henriksen, EJ 2008, 'Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat', Metabolism: Clinical and Experimental, vol. 57, no. 10, pp. 1465-1472. https://doi.org/10.1016/j.metabol.2008.05.018
Muellenbach, Elizabeth A. ; Diehl, Cody J. ; Teachey, Mary K. ; Lindborg, Katherine A. ; Archuleta, Tara L. ; Harrell, Nicholas B. ; Andersen, Gaby ; Somoza, Veronika ; Hasselwander, Oliver ; Matuschek, Markus ; Henriksen, Erik J. / Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat. In: Metabolism: Clinical and Experimental. 2008 ; Vol. 57, No. 10. pp. 1465-1472.
@article{7697916647564b4382ae538c763cfb3b,
title = "Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat",
abstract = "Oxidative stress and protein glycation can contribute to the development of insulin resistance and complications associated with type 2 diabetes mellitus. The antioxidant α-lipoic acid (ALA) reduces oxidative stress and the formation of advanced glycation end products (AGEs) and improves insulin sensitivity in skeletal muscle and liver. The AGE inhibitor pyridoxamine (PM) prevents irreversible protein glycation, thereby reducing various diabetic complications. The potential interactive effects of ALA and PM in the treatment of whole-body and skeletal muscle insulin resistance have not been investigated. Therefore, this study was designed to determine the effects of combined ALA and PM treatments on reducing muscle oxidative stress and ameliorating insulin resistance in prediabetic obese Zucker rats. Obese Zucker rats were assigned to either a control group or to a treatment group receiving daily injections of the R-(+)-enantiomer of ALA (R-ALA, 92 mg/kg) or PM (60 mg/kg), individually or in combination, for 6 weeks. The individual and combined treatments with R-ALA and PM were effective in significantly (P < .05) reducing plantaris muscle protein carbonyls (33{\%}-40{\%}) and urine-conjugated dienes (22{\%}-38{\%}), markers of oxidative stress. The R-ALA and PM in combination resulted in the largest reductions of fasting plasma glucose (23{\%}), insulin (16{\%}), and free fatty acids (24{\%}) and of muscle triglycerides (45{\%}) compared with alterations elicited by individual treatment with R-ALA or PM. Moreover, the combination of R-ALA and PM elicited the greatest enhancement of whole-body insulin sensitivity both in the fasted state and during an oral glucose tolerance test. Finally, combined R-ALA/PM treatments maintained the 44{\%} enhancement of in vitro insulin-mediated glucose transport activity in soleus muscle of obese Zucker rats treated with R-ALA alone. Collectively, these results document a beneficial interaction of the antioxidant R-ALA and the AGE inhibitor PM in the treatment of whole-body and skeletal muscle insulin resistance in obese Zucker rats.",
author = "Muellenbach, {Elizabeth A.} and Diehl, {Cody J.} and Teachey, {Mary K.} and Lindborg, {Katherine A.} and Archuleta, {Tara L.} and Harrell, {Nicholas B.} and Gaby Andersen and Veronika Somoza and Oliver Hasselwander and Markus Matuschek and Henriksen, {Erik J}",
year = "2008",
month = "10",
doi = "10.1016/j.metabol.2008.05.018",
language = "English (US)",
volume = "57",
pages = "1465--1472",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat

AU - Muellenbach, Elizabeth A.

AU - Diehl, Cody J.

AU - Teachey, Mary K.

AU - Lindborg, Katherine A.

AU - Archuleta, Tara L.

AU - Harrell, Nicholas B.

AU - Andersen, Gaby

AU - Somoza, Veronika

AU - Hasselwander, Oliver

AU - Matuschek, Markus

AU - Henriksen, Erik J

PY - 2008/10

Y1 - 2008/10

N2 - Oxidative stress and protein glycation can contribute to the development of insulin resistance and complications associated with type 2 diabetes mellitus. The antioxidant α-lipoic acid (ALA) reduces oxidative stress and the formation of advanced glycation end products (AGEs) and improves insulin sensitivity in skeletal muscle and liver. The AGE inhibitor pyridoxamine (PM) prevents irreversible protein glycation, thereby reducing various diabetic complications. The potential interactive effects of ALA and PM in the treatment of whole-body and skeletal muscle insulin resistance have not been investigated. Therefore, this study was designed to determine the effects of combined ALA and PM treatments on reducing muscle oxidative stress and ameliorating insulin resistance in prediabetic obese Zucker rats. Obese Zucker rats were assigned to either a control group or to a treatment group receiving daily injections of the R-(+)-enantiomer of ALA (R-ALA, 92 mg/kg) or PM (60 mg/kg), individually or in combination, for 6 weeks. The individual and combined treatments with R-ALA and PM were effective in significantly (P < .05) reducing plantaris muscle protein carbonyls (33%-40%) and urine-conjugated dienes (22%-38%), markers of oxidative stress. The R-ALA and PM in combination resulted in the largest reductions of fasting plasma glucose (23%), insulin (16%), and free fatty acids (24%) and of muscle triglycerides (45%) compared with alterations elicited by individual treatment with R-ALA or PM. Moreover, the combination of R-ALA and PM elicited the greatest enhancement of whole-body insulin sensitivity both in the fasted state and during an oral glucose tolerance test. Finally, combined R-ALA/PM treatments maintained the 44% enhancement of in vitro insulin-mediated glucose transport activity in soleus muscle of obese Zucker rats treated with R-ALA alone. Collectively, these results document a beneficial interaction of the antioxidant R-ALA and the AGE inhibitor PM in the treatment of whole-body and skeletal muscle insulin resistance in obese Zucker rats.

AB - Oxidative stress and protein glycation can contribute to the development of insulin resistance and complications associated with type 2 diabetes mellitus. The antioxidant α-lipoic acid (ALA) reduces oxidative stress and the formation of advanced glycation end products (AGEs) and improves insulin sensitivity in skeletal muscle and liver. The AGE inhibitor pyridoxamine (PM) prevents irreversible protein glycation, thereby reducing various diabetic complications. The potential interactive effects of ALA and PM in the treatment of whole-body and skeletal muscle insulin resistance have not been investigated. Therefore, this study was designed to determine the effects of combined ALA and PM treatments on reducing muscle oxidative stress and ameliorating insulin resistance in prediabetic obese Zucker rats. Obese Zucker rats were assigned to either a control group or to a treatment group receiving daily injections of the R-(+)-enantiomer of ALA (R-ALA, 92 mg/kg) or PM (60 mg/kg), individually or in combination, for 6 weeks. The individual and combined treatments with R-ALA and PM were effective in significantly (P < .05) reducing plantaris muscle protein carbonyls (33%-40%) and urine-conjugated dienes (22%-38%), markers of oxidative stress. The R-ALA and PM in combination resulted in the largest reductions of fasting plasma glucose (23%), insulin (16%), and free fatty acids (24%) and of muscle triglycerides (45%) compared with alterations elicited by individual treatment with R-ALA or PM. Moreover, the combination of R-ALA and PM elicited the greatest enhancement of whole-body insulin sensitivity both in the fasted state and during an oral glucose tolerance test. Finally, combined R-ALA/PM treatments maintained the 44% enhancement of in vitro insulin-mediated glucose transport activity in soleus muscle of obese Zucker rats treated with R-ALA alone. Collectively, these results document a beneficial interaction of the antioxidant R-ALA and the AGE inhibitor PM in the treatment of whole-body and skeletal muscle insulin resistance in obese Zucker rats.

UR - http://www.scopus.com/inward/record.url?scp=51649097664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649097664&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2008.05.018

DO - 10.1016/j.metabol.2008.05.018

M3 - Article

C2 - 18803954

AN - SCOPUS:51649097664

VL - 57

SP - 1465

EP - 1472

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -